Trending...
- Sea Tales Strengthens U.S. Leadership Team as Retail Expansion Accelerates
- Robert DeMaio, Phinge CEO to Speak at 30th IIPLA 2026 on Securing IP, User Data & Digital Sovereignty via Verified App-less Tech. Attend the Live Q&A!
- Amaris Mint® Confirms UK Availability of Swedish-Made BioBoost Daily Nutrition Range
Will Present Clinical Development Plans For Several Novel Therapeutic Agents Derived from Human Microbiome
PHILADELPHIA - illiNews -- SFA Therapeutics, Inc. announced today that their CEO, Dr. Ira Spector, will update the company's clinical development plans for several new therapeutic agents they have derived from the human microbiome. The presentation will be delivered as part of the prestigious Bio Investors Forum on October 23rd at 9:45AM in the Elizabethan Room of the Westin St. Francis Hotel in San Francisco, CA.
About SFA Therapeutics
SFA Therapeutics, Inc. is a bio-pharmaceutical company focused on new human-microbiome-based advancements in the treatment of inflammatory diseases, targeting NF-kB and RAS. Chronic inflammation has been implicated in a wide range of diseases, including HCC, Psoriatic Arthritis, Rheumatoid Arthritis, Lupus (SLE), Inflammatory Bowel Disease (IBD), Crohn's Disease, Liver Disease and relapse/recurrence in AML and CML. SFA currently has five drugs under development, and is targeting psoriasis, Hepatitis B and Hepatocellular Carcinoma (liver cancer) with their lead assets.
More on illi News
SFA's small-molecule drugs are derived from natural substances produced in the human microbiome and enable a new platform for developing safer treatments for inflammatory diseases. SFA's drug development platform has been exclusively licensed from Temple University to SFA Therapeutics in Jenkintown, PA. Please visit www.sfatherapeutics.com to learn more.
About SFA Therapeutics
SFA Therapeutics, Inc. is a bio-pharmaceutical company focused on new human-microbiome-based advancements in the treatment of inflammatory diseases, targeting NF-kB and RAS. Chronic inflammation has been implicated in a wide range of diseases, including HCC, Psoriatic Arthritis, Rheumatoid Arthritis, Lupus (SLE), Inflammatory Bowel Disease (IBD), Crohn's Disease, Liver Disease and relapse/recurrence in AML and CML. SFA currently has five drugs under development, and is targeting psoriasis, Hepatitis B and Hepatocellular Carcinoma (liver cancer) with their lead assets.
More on illi News
- CodeAutomation Expands U.S. Footprint to Meet Growing Demand for AI and Automation Solutions
- HydroExcavation.com Relaunches With Exclusive Local Service Areas and Dedicated Hydrovac Manufacturer Directory
- Sky Quarry Enters a Powerful New Chapter: Refinery Restart Emminent, Nevada Oil Initiative and Visibility Put (NAS DAQ: SKYQ) in the Spotlight
- OneVizion Launches Vera AI, Bringing Connected Operational Context to Infrastructure Teams
- P-Wave Press Announces Pushing the Wave 2025 by L.A. Davenport
SFA's small-molecule drugs are derived from natural substances produced in the human microbiome and enable a new platform for developing safer treatments for inflammatory diseases. SFA's drug development platform has been exclusively licensed from Temple University to SFA Therapeutics in Jenkintown, PA. Please visit www.sfatherapeutics.com to learn more.
Source: SFA Therapeutics, Inc.
0 Comments
Latest on illi News
- Defense & Space Strategy Strengthens as New Leadership Builds on NASA Results and Expanding Multi-Orbit Opportunities for Ascent Solar Technologies
- Chicago: Mayor Brandon Johnson, R2 Development Celebrate Grand Opening of The Bellwether, First Completed Office to Residential Conversion in The Loop
- Chicago: Mayor Brandon Johnson, DFSS Launch Disaster Relief Assistance Program for People Who Faced Financial Hardship Due to Severe Storms in 2023 and 2024
- Mayor Brandon Johnson, City Officials, and Community Leaders Outline Plans For Chicago's 2026 Mexican Independence Day Celebrations
- STS Capital Partners is pleased to announce the appointment of Barry Brown as Vice President, Business Development
- Qscription Technologies and NEOPATHOLOGY CORP. Sign MOU to Bring FDA-Cleared Lung Imaging AI into U.S. Clinical Practice
- Howe & Hutton Closes; Jonathan T. Howe Transitions to Association Law Group LLC
- Naperville: Police Investigate Report of Gunshots
- Aerostratospheric Adds xAirship and Other Shop Test Units to Its xPrototypes Bench
- Firebox Encapsulator Introduces a New Approach to Fireplace Restoration
- Merlin's Pet Therapy Wrap Introduces a Versatile Approach to Hot and Cold Therapy for Dogs
- Heritage at Manalapan Welcomes New Sales Team as Luxury Single-Family Home Community Continues to Grow
- Patented NogginLOC Technology Offers an Innovative Approach to Helmet Fastening
- Mandeville Pests May Pose Serious Health Risks for Your Family
- City of Chicago Partners With Chicago River Swim to Re-Launch "The Big Jump," Expand Field to 750 Swimmers
- Mayor Brandon Johnson and Chicago Public Schools Extend Chicago Connected Program for 2026–27 School Year
- Hardwood Flooring vs Carpet Comparison: Premier Custom Hardwood Flooring Releases Ultimate Buyer's Guide
- The Kryder Law Group, LLC Recovers $1,350,000 in Two Motorcycle Accident Settlements
- Share your workplace safety solutions at 2027 Applied Ergonomics Conference
- Parents No Longer Have to Wait 3 Weeks for a Sleep Consultant: Nora Talks Tonight, Stays for 5 Days, Costs $89